Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer

NCT05197322 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05197322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05197322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 20, 2022
Completion date
November 1, 2029
Enrollment
88 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the colon